文献速递流行病学与生物统计医学教育与科研方法

成人注意缺陷多动障碍缓释哌甲酯的监管文件中缺失临床试验:一项公开文件案例研究

Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents.
PubMed 文献 · J Clin Epidemiol · 2021-11-06

该案例系列研究将18项缓释哌甲酯治疗成人注意缺陷多动障碍的试验与7个机构发布的13份药品申请监管文件进行匹配,发现7份(54%)申请缺失试验,中位缺失4项(范围1-6),缺失试验参与者比例中位45%(范围23%-72%)。尽管监管要求似乎规定所有可用试验均应纳入申请,但措辞含糊。

要点

  • 13份缓释哌甲酯成人注意缺陷多动障碍药品申请中,7份(54%)的公开监管文件缺失整个试验。
  • 每份缺失试验的申请中,中位缺失4项试验(范围1-6),缺失参与者比例中位45%(范围23%-72%)。
  • 监管机构似乎要求所有试验均须纳入新药申请,但措辞含糊。

核心结论

  • 在该缓释哌甲酯成人注意缺陷多动障碍药品申请样本中,根据公开文件,13项监管决定中有7项缺失整个试验,尽管监管要求似乎规定所有可用试验均应纳入药品申请。

研究设计与样本

  • 公开监管文件的案例系列研究,试验与监管文件通过系统评价(https://doi.org/10.1002/14651858.CD012857)识别。
  • 索引18项试验,并与7个机构发布的13份药品申请(11份批准,2份拒绝)匹配。

主要发现

  • 13份申请中7份(54%)缺失试验,中位缺失4项试验(范围1-6)。
  • 缺失试验参与者比例中位45%(范围23%-72%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess whether drug regulatory agencies decided on applications for extended-release methylphenidate for use in adult ADHD based on select samples of trials. STUDY DESIGN AND SETTING: Case series of publicly available regulatory documents. We matched an index of extended-release methylphenidate trials for adult ADHD with trials appearing in regulatory documents of extended-release methylphenidate applications. Trials and regulatory documents were identified as part of this systematic review (https://doi.org/10.1002/14651858.CD012857). We sought to identify missing trials in the regulatory documents and to clarify regulatory submission requirements. RESULTS: We indexed 18 trials and matched those with 13 drug applications (11 approved, 2 rejected) published by 7 agencies. There were trials missing in 7 (54%) of 13 applications, median 4 trials (range 1-6). The median proportion of missing trial participants was 45% (range 23% - 72%). Regulators seemingly require that all trials must be included in new drug applications, but wording is ambiguous. CONCLUSION: In this sample of extended-release methylphenidate drug applications for adult ADHD, 7 of 13 regulatory decisions were missing entire trials according to public documents, even though regulatory requirements seem to stipulate that all available trials should be included in drug applications.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Boesen K, Jørgensen KJ, Gøtzsche PC, et al. Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents. J Clin Epidemiol. 2021. PMID: 34752938. doi:10.1016/j.jclinepi.2021.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。